Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...

Vertex Pharmaceuticals has been attracting investor attention due to strong recent stock performance. The company's shares ...

Investing.com -- Maze Therapeutics Inc (NASDAQ: MAZE ) received bullish coverage from multiple analysts, with Guggenheim, ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

Handelsbanken Fonder AB reduced its stake in Vertex Pharmaceuticals by 28.1% in Q4, selling 115,479 shares. The fund now owns ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...